ArticleJournal of pharmaceutical health care and sciences2025
Identification of high-risk age groups for cisplatin-induced nausea and vomiting in young patients with sarcoma.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYoung age has been reported as a patient-related risk factor for chemotherapy-induced nausea and vomiting (CINV). However, there have been few reports of the status of CINV limited to younger patients. In this study, CINV status after cisplatin administration was investigated in young patients with sarcoma.
methodsThis retrospective, observational study included patients younger than 65 years with sarcoma who received cisplatin-containing chemotherapy at the Department of Orthopaedic Surgery, Cancer Institute Hospital Ariake, Japan, between January 2011 and December 2020. The evaluated endpoints were the complete response (CR) rate, defined as no emesis and no use of rescue antiemetics, and the no-vomiting rate, defined as no emesis regardless of rescue antiemetic use, in three age groups: children (< 15 years), adolescent and young adult (AYA; ≥15 to < 40 years), and middle age (MA; ≥40 to ≤ 64 years).
resultsTwenty patients in the children group, 32 in the AYA group, and 19 in the MA group were included in the analysis. CR rates overall and in the delayed phase were 20% (4/20) in the children group, 28.1% (9/32) in the AYA group, and 42.1% (8/19) in the MA group. CR rates in the acute phase were 70% (14/20) in the children group, 78.1% (25/32) in the AYA group, and 94.7% (18/19) in the MA group. No-vomiting rates overall and in the delayed phase were 50.0% (10/20) in the children group, 59.4% (19/32) in the AYA group, and 78.9% (15/19) in the MA group. No-vomiting rates in the acute phase were 95.0% (19/20) in the children group, 96.9% (31/32) in the AYA group, and 100% (19/19) in the MA group.
conclusionEven in patients younger than 65 years, the risk of CINV seemed higher in younger age groups.
trial registrationRetrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.